Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141379 |
| CAS No | NA |
| Mol.F. | C15H12Cl2N2O5 |
| Mol.Wt. | 371.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141380 |
| CAS No | NA |
| Mol.F. | C16H14Cl2N2O5 |
| Mol.Wt. | 385.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141381 |
| CAS No | NA |
| Mol.F. | C17H16Cl2N2O5 |
| Mol.Wt. | 399.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141382 |
| CAS No | NA |
| Mol.F. | C17H22ClN4O2 |
| Mol.Wt. | 364.87 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141383 |
| CAS No | NA |
| Mol.F. | C26H32N2O7 |
| Mol.Wt. | 484.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141384 |
| CAS No | NA |
| Mol.F. | C9H10ClN7O3 |
| Mol.Wt. | 299.7 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141385 |
| CAS No | NA |
| Mol.F. | C9H10ClN7O3 |
| Mol.Wt. | 299.7 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141386 |
| CAS No | NA |
| Mol.F. | C5H11N3O |
| Mol.Wt. | 129.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141387 |
| CAS No | NA |
| Mol.F. | C19H21FN4O5 |
| Mol.Wt. | 404.4 g/mol |
| INV STATUS | In Stock |
| CAT No | SRC-N0141388 |
| CAS No | NA |
| Mol.F. | C5H13N3O2 |
| Mol.Wt. | 147.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141389 |
| CAS No | NA |
| Mol.F. | C19H20BF3N4O5 |
| Mol.Wt. | 452.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141390 |
| CAS No | NA |
| Mol.F. | C13H10F2N2O5 |
| Mol.Wt. | 312.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141391 |
| CAS No | NA |
| Mol.F. | C19H18FN3O2 |
| Mol.Wt. | 339.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141392 |
| CAS No | NA |
| Mol.F. | C19H16FN3O3 |
| Mol.Wt. | 353..4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141393 |
| CAS No | NA |
| Mol.F. | C19H20FN3O3 |
| Mol.Wt. | 357.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141394 |
| CAS No | NA |
| Mol.F. | C19H18FN3O3 |
| Mol.Wt. | 355.4 |
| INV STATUS | CUSTOM SYNTHESIS |